Market closed
Celcuity/$CELC
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Celcuity
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
Ticker
$CELC
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
87
ISIN
US15102K1007
Website
Celcuity Metrics
BasicAdvanced
$398M
-
-$3.04
0.56
-
Price and volume
Market cap
$398M
Beta
0.56
52-week high
$19.77
52-week low
$7.58
Average daily volume
260K
Financial strength
Current ratio
6.61
Quick ratio
6.248
Long term debt to equity
113.698
Total debt to equity
113.893
Interest coverage (TTM)
-10.52%
Management effectiveness
Return on assets (TTM)
-39.04%
Return on equity (TTM)
-115.39%
Valuation
Price to book
5.23
Price to tangible book (TTM)
5.23
Growth
Earnings per share change (TTM)
10.40%
3-year earnings per share growth (CAGR)
7.88%
What the Analysts think about Celcuity
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Celcuity stock.
Celcuity Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Celcuity Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Celcuity News
AllArticlesVideos
Celcuity Inc. (CELC) Q1 2025 Earnings Call Transcript
Seeking Alpha·2 days ago
Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewsWire·2 days ago
Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call
GlobeNewsWire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Celcuity stock?
Celcuity (CELC) has a market cap of $398M as of May 16, 2025.
What is the P/E ratio for Celcuity stock?
The price to earnings (P/E) ratio for Celcuity (CELC) stock is 0 as of May 16, 2025.
Does Celcuity stock pay dividends?
No, Celcuity (CELC) stock does not pay dividends to its shareholders as of May 16, 2025.
When is the next Celcuity dividend payment date?
Celcuity (CELC) stock does not pay dividends to its shareholders.
What is the beta indicator for Celcuity?
Celcuity (CELC) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.